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 Introduction 
 Nephrology as a general discipline, compared to 12 other major 
medical subspecialties, ranks at the bottom in the performance 
and completion of randomized clinical trials (RCT). 1 Th ere 
are a number of potential explanations for this suboptimal 
implementation of clinical research trial opportunities. First, 
the diseases of interest are generally uncommon necessitating 
multicenter studies. Second, patients with early chronic kidney 
disease (CKD) are oft en asymptomatic and may not appreciate 
the presence or severity of the underlying disease or the long-
term threat that it represents to their health, features that may 
adversely impact patient motivation to enroll in research projects. 
Th ird, because of the considerable gap in our understanding of the 
pathogenesis of most kidney diseases there is a paucity of discrete 
targets and novel options for the safe and eff ective treatment of 
most disorders. Fourth, many nephrology services do not have 
adequate personnel and resources allocated to the performance 
of clinical research. Fift h, although RCTs are considered the “gold 
standard,” they are expensive and time-consuming. 2 Finally, there 
is no organized infrastructure in nephrology comparable to the 
oncology study groups, neonatal network, or acute respiratory 
disease collaborative that can facilitate the performance of RCTs 
for the full spectrum of rare kidney diseases. 
 In the face of these challenges, there remains a pressing need 
to conduct RCTs to guide the optimal utilization of available 
therapies and to test novel treatments for pediatric and adult 
patients with kidney diseases. Th is is especially critical for those 
conditions whose natural history include the progression to end-
stage kidney disease (ESKD), or recurrence of the disease aft er 
kidney transplantation. ESKD represents one of the most costly 
medical conditions due to intense patient disease burden, impact 
on quality of life and the high-fi nancial cost to society ( http://
www.usrds.org/2011/view/v2_11.asp ). 
 Successful performance of RCTs provides optimal evidence 
about the effi  cacy of commonly used but untested interventions 
and helps clarify meaningful outcomes when testing newer 
therapeutic options. Unfortunately, many RCTs do not 
meet projected recruitment targets and, therefore, they are 
underpowered to achieve their primary and main secondary 
end points. 3 Although novel trial designs and alternative methods 
of statistical analysis such as Bayesian approaches may decrease 
the required sample size requirements, 4 it is important to identify 
impediments to successful pediatric and adult patient accrual 
and completion of RCTs. 
 Th e focal segmental glomerulosclerosis clinical trial (FSGS 
CT), funded by the National Institutes of Diabetes and Digestive 
and Kidney Diseases of the US National Institutes of Health UO1 
grant mechanism, included 138 patients with primary steroid-
resistant FSGS over a 5-year period. Participants were randomized 
to one of two treatment arms—cyclosporine versus mycophenolate 
mofetil and dexamethasone. However, it fell far short of its 
anticipated goal of 500 participants. Even though the study is 
the largest RCT that has ever been conducted in patients with this 
condition in North America, the validity and interpretation of the 
fi ndings have been hampered by the limited enrollment. 5,6,7 Th is 
report prepared by the Recruitment and Retention Committee 
(RRC) of the FSGS CT is intended to achieve the following 
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 Abstract 
 We describe the experience of the focal segmental glomerulosclerosis clinical trial (FSGS CT) in the identifi cation and recruitment of 
participants into the study. This National Institutes of Health funded study, a multicenter, open-label, randomized comparison of cyclo-
sporine versus oral dexamethasone pulses plus mycophenolate mofetil, experienced diffi culty and delays meeting enrollment goals. 
These problems occurred despite the support of patient advocacy groups and aggressive recruitment strategies. Multiple barriers were 
identifi ed including: (1) inaccurate estimates of the number of potential incident FSGS patients at participating centers; (2) delays in 
securing one of the test agents; (3) prolonged time between IRB approval and execution of a subcontract (mean 7.5 ± 0.8 months); 
(4) prolonged time between IRB approval and enrollment of the fi rst patient at participating sites (mean 19.6 ± 1.4 months); and (5) 
reorganization of clinical coordinating core infrastructure to align resources with enrollment. A Web-based anonymous survey of site 
investigators revealed site-related barriers to patient recruitment. The value of a variety of recruitment tools was of marginal utility in 
facilitating patient enrollment. We conclude that improvements in the logistics of study approval and regulatory start-up and testing of 
promising novel agents are important factors in promoting enrollment into randomized clinical trials in nephrology. Clin Trans Sci 2013; 
Volume 6: 13–20
 Keywords:  clinical trials ,  kidney ,  nephrology ,  pediatrics 
14 VOLUME 6 • ISSUE 1 WWW.CTSJOURNAL.COM
 Ferris et al. ■  Recruitment into the FSGS Clinical Trial 
any proposed experimental intervention rather than a placebo 
arm. Th is led to an extensive review of the literature to defi ne 
the standard of care for patients with FSGS and to delineate 
reasonable options for the active control and test therapy that 
would be acceptable to the largest majority of participating 
investigators. Based on this survey of the existing literature and 
participating site survey results, treatment arms were selected 
and the full trial design protocol and manual of operations were 
completed. Responses were received from 91 sites (50% response 
rate)—67 PED and 24 IM practices, providing information about 
the number of incident patients with primary FSGS who had been 
treated between 2001 and 2002. Th e total number of incident 
primary FSGS cases at all surveyed sites was 479 in 2001 and 481 
in 2002. Th e mean number of cases per site was 5.8 ± 9.2 in 2001 
and 5.9 ± 9.2 in 2002 ( Figure 1 ). Nearly 67% of the sites had 1–5 
patients in each year and nine (10%) sites had 10–60 patients in 
both years of the survey period. Based on these projections, the 
Steering Committee anticipated that 500 patients with incident 
primary FSGS could be successfully enrolled into the FSGS CT 
over a 26-month period, assuming a 50% enrollment rate. Th is 
sample size would enable the study to achieve an 80% power 
to detect a 12% diff erence in the response rate between the 
control cyclosporine treatment arm and the experimental arm 
consisting of the combination of oral dexamethasone pulses and 
mycophenolate mofetil. 
 Th e NIH charge to the FSGS CT Steering Committee was to 
include children and young adults in the trial. Th erefore, patients 
between the ages of 2–40 years were targeted at sites with PED 
and/or IM practices. To include adolescents and young adults who 
were under the care of IM nephrologists, a list of these practitioners 
was grouped separately from sites that treated only PED or IM 
patients. Th e major source of IM practices was the Glomerular 
Disease Collaborative Network (a research collaborative based 
at UNC-Chapel Hill); however, other IM practices that treated 
older pediatric and young adult patients from around the United 
States were represented. 
 Donation of one of the study drugs to be tested in the trial 
had been pledged by the pharmaceutical company during the 
four objectives: (1) describe the methodology used during the 
planning phase of the RCT to estimate the anticipated patient 
enrollment and optimal trial design; (2) analyze the recruitment 
activity at all participating sites in the clinical trial; (3) summarize 
the time course of site activation and patient recruitment; and (4) 
conduct a  post hoc survey of site investigators regarding factors 
that aff ected patient enrollment. 
 Methods 
 Before the trial was implemented, several strategies were 
employed to maximize enrollment including: (1) collaboration 
with a patient advocacy group—the NephCure Foundation; (2) 
deploying a survey of participating sites about the number of 
potential study participants who would be candidates for the RCT 
and the feasibility and acceptability of trial interventions options 
across pediatric (PED) and internal medicine (IM) nephrologists. 
Th e second component was assessed to increase engagement 
and consensus among potential investigators in nephrology 
practices. 
 A prestudy survey of investigators was conducted to estimate 
the number of potential study participants and determine the 
acceptability of potential treatment options and drug regimens 
by managing physicians in rank order. Although the FSGS CT 
initially consisted of fi ve core sites, the fi ndings are presented for 
the three consolidated core centers that ultimately supervised 
enrollment of patients into the trial. 
 To identify facilitators and barriers to enrollment into the 
FSGS CT, a third-party anonymous Web-based survey of physician 
investigators was deployed aft er the completion of the trial and 
publication of the primary outcome. Investigators were asked 
about the impact of a number of factors on recruitment at their 
site (See Appendix). Th ese included achieving a consensus within 
their division to be part of the study, IRB approval, executing 
the contract, support from the clinical cores, availability of the 
core coordinators, adequacy of start up funds, adequacy of 
reimbursement, and availability of supplemental funds at the 
sites. Th e responses were recorded on a 5-point Likert scale (1, 
major impediment; 3, neutral; and 5, major help). Th e survey was 
deployed three times using Qualtrics and respondents had the 
option to participate in a drawing for 100 US dollars. 
 Results are expressed as frequencies and mean ± standard 
error of the mean (SEM). Th e survey responses from those who 
enrolled at least 1 patient were compared with those who failed 
to enter a single study participant, using chi-square analysis. 
 Results 
 Planning phase 
 Th e NephCure Foundation advocated for a trial for the treatment 
of FSGS before the allocation of funding and request for trial 
proposals issued by the NIH as a part of the U01 mechanism. 
Following NIH peer review and selection of the trial leadership, 
collaboration with the patient advocacy group continued with 
dissemination of information about the trial on their Website, 
newsletters and other publications, community educational 
events, and partnership to fund ancillary research eff orts focused 
on genetics and FSGS. 
 During the planning phase for the FSGS CT, the Steering 
Committee participated in several in-person, day-long meetings 
to draft  an acceptable protocol. Th e NIH guidelines for the trial 
mandated an active control treatment for comparison with 
 Figure 1.  Number of patients reported to have been seen in years 2001–2002 
(projected enrollment) and the number of at PED and IM sites entered into the 
study (actual enrollment). 
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planning phase of the FSGS-CT. Aft er the trial had been funded 
and aft er more than 12 months of negotiations with the company, 
this donation was rescinded. As a result, the NIDDK was forced 
to purchase the specifi c study medication. 
 Analysis of site recruitment 
 Of the 116 potential sites that initially off ered to participate in the 
trial, 104 sites (90%) obtained IRB approval and met the logistic 
requirements to enroll patients. Th ere were 52 PED sites, 26 
MED sites, and 26 sites that treated both groups of patients. All 
of these centers had an executed contract in place for payment 
of the clinical eff ort required by the study. At least one patient 
was successfully enrolled into the study at 53 (51%) participating 
centers. Th e majority ( n = 37) enrolled 1–3 patients and 16 sites 
enrolled 4 or more participants. Th e mean number of PED 
patients enrolled at each site was 1.2 ± 0.2 and the mean number 
of IM patients enrolled per site was 0.5 ± 0.1. Overall, the mean 
enrollment per site was only 29% of the projected number of 
participants, for example, 1.7/5.9 ( Figure 1 ). Th e three centers 
that recruited the most patients into the trial were located in 
the Bronx, NY, New Hyde Park, NY, and Chapel Hill, NC, and 
they also served as the three Clinical Coordinating Centers for 
the study. Th e geographic distribution of the patients who were 
enrolled in the FSGS CT, based on the zip code of the participating 
site is illustrated in  Figure 2 . 
 During the course of the FSGS CT, 192 patients were enrolled 
and 54 were subsequently excluded from the study. Th e two 
most common reasons for this course of events were a level of 
proteinuria that was below the inclusion criterion ( n = 20) and 
failure to confi rm the diagnosis of primary FSGS aft er central 
review of the kidney biopsy by a study pathologist ( n = 22). 7 
During the course of the trial, the level of proteinuria needed 
to qualify for enrollment was lowered from 2 to 1 (protein [g]/
creatinine [g]) to promote recruitment. Th ere was no systematic 
attempt to monitor encounters with all patients who qualifi ed 
but declined to participate in the study. 
 Study activation 
 Th e FSGS CT offi  cially opened to patient enrollment on November 
18, 2004. Th e mean time to obtain IRB approval among the 
participating sites was 1.9 ± 5.1 months. An important barrier to 
the timely opening of the study was a delay of over 12 months due 
to administrative diffi  culties in securing one of the test agents. Th e 
mean interval that elapsed between obtaining IRB approval and 
executing a subcontract to support the clinical research activity 
was 7.5 ± 0.8 months. In total, the median time from distribution 
of the fi nal protocol to completion of all necessary regulatory 
requirements and enrollment of the fi rst patient at a participating 
site was 19.6 ± 1.4 months ( Figure 3 ). 
 Eff orts to increase recruitment 
 Enrollment into the FSGS CT was slow from the onset of the 
study and, therefore the enrollment period was extended from 
26 to 40 months in an attempt to foster recruitment. Over the 
course of the FSGS CT and in response to low enrollment, 
aggressive marketing eff orts were increased by (1) updating 
the study Website, (2) creating a low-literacy and culturally 
appropriate short video (10 minutes) in English and Spanish that 
featured clinicians and patients who participated in the RCT; 
(3) quarterly newsletters; (4) investigators lectures within the 
medical community; (5) inviting site investigators to participate 
in trial leadership committees; (6) expanding the eligibility 
criteria (higher age and BMI cutoff s, lower eGFR cutoff , altered 
defi nition of steroid resistance and lower qualifying level of 
proteinuria); and (7) engagement of nephropathologists to assist 
with identifi cation of potential patients from biopsy diagnosis. 
No signifi cant improvement in enrollment was observed with 
these approaches 
 Figure 2.  Geographical distribution of the patients who were enrolled in the FSGS based on the zip code of the participating site where they were treated. 
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 Post hoc recruitment survey of site investigators 
 Responses were received from 47 (45%) of the 104 sites that 
obtained IRB approval for the study and were logistically ready to 
enroll patients. Of the respondents, 39 completed all of questions, 
but only 40% chose to enter their name in the incentive lottery. 
Most respondents worked in academic centers (87%) and the rest 
(13%) were in private practice. Th e majority of respondents enrolled 
exclusively PED patients (61%) or a combination of children 
and adults (18%). Only 21% of the respondents were from IM 
nephrology sites, mostly from the Eastern United States. Although 
the vast majority of sites used their local or core IRB (86%), most 
of the IM participants obtained approval from a central IRB. 
 The scores on achieving practice group consensus, IRB 
approval/contract-related issues, clinical core support, and 
adequacy of start-up/patient reimbursement expenses ranged 
from 2.4 to 3.3 out of 5 (most helpful) in the Likert scale. Th e 
item with the lowest score was availability of supplemental funds 
at the participating site (2.4 ± 1.0) and none of the items were 
considered either a minor or major help. 
 When asked about the value of the recruitment tools on 
a 1–4 scale (1, not at all; 4, absolutely helpful), the two most 
helpful interventions to promote enrollment were the video 
that introduced the trial (3.7 ± 1.6) and participation in trial 
leadership committees (3.7 ± 1.5) whereas the least helpful were 
newsletters (2.8 ± 1.3) and brochures (2.9 ± 1.3). Th e investigators 
were queried about whether they thought any of the eligibility 
criteria had an adverse eff ect on enrollment. On a scale of 1–4 (1, 
not at all; 4, absolutely), none of the features had a mean score 
above 2.7. Th e item with the highest score (2.7 ± 1.1) was prior 
treatment with one of the study medications. A summary of some 
of the key recurrent free text answers is provided in the  Table 1 . 
 Th e survey responses from the 19 sites (16, 84% in academic 
settings) that enrolled at least 1 patient (mean of 4.3 ± 4.3 patients) 
were compared with 20 responses from sites that failed to enter a 
single study participant (18, 90% in academic settings). Nonenrolling 
sites scored support from the core center lower than enrolling sites, 
OR = 5.9, 95% [CI 1.3–27.3] ( p < 0.05). Th eir identifi ed facilitators/
barriers and open-ended responses are summarized in the  Table 1 . 
 Discussion 
 Th e FSGS CT was the largest multicenter RCT ever performed in 
North America to address the management of this challenging 
medical condition. The overall 
design with two active treatment 
arms refl ected the input of patients 
and families with FSGS who lobbied 
the federal government to support 
an RCT for this glomerular disease. 
It featured close collaboration 
between pediatric and IM 
nephrologists. Th e implementation 
of the RCT was consolidated 
into three central cores and was 
organized in a manner to facilitate 
communication and data transfer 
from the participating sites to 
the data coordinating center 
with the assistance of the clinical 
coordinating centers. 6,7 
 Overall, recruitment achieved 
only 138 of 500 projected patients, 
28% of the target sample size. In large measure, this refl ected the 
overly optimistic projections of potential participants at each site. 
In fact, actual enrollment was approximately 30% of the number 
of patients who had been seen at participating sites in the 2 years 
before initiation of the study. Th ere is no apparent explanation 
for this acute drop off  in incidence of primary FSGS at the broad 
list of potential sites. However, it is conceivable that the pretrial 
estimates of potential patients at each site included both primary 
and secondary causes of FSGS and did not account for the study 
eligibility criteria adopted by the trial. Alternatively, the original 
estimates may have been overly optimistic and the incidence of 
FSGS did not decline during the study period. Th is barrier could 
be resolved by having longitudinal patient databases/registries 
that can be queried when clinical trials are proposed. 
 Despite the inclusion of patient and patient-advocacy groups’ 
input as well as aggressive marketing and communications 
strategies, a number of barriers that were beyond the control of the 
 Figure 3.  Timeline of FSGS CT study outlining key events in the set up and performance of the study. 
General
 • Low prevalence of disease at site
 • Presentation with advanced renal disease
 •  Patient unwillingness to maintain randomized treatment if 
there is no immediate evidence of effi cacy
Medications
 • Prior exposure to study drugs
 • Concern about exposure to steroids, especially in adults
 •  Choice of specifi c study drugs, e.g. cyclosporine versus 
tacrolimus
 • Specifi c doses of study drugs
Study design
 •  Requirement for confi rmation of FSGS on stored biopsy 
material
 •  Exclusion of patients with steroid resistance but histological 
evidence of minimal change nephrotic syndrome
 • Specifi c eligibility criteria—age, BMI, eGFR
 • Rigid standards for blood pressure control
 Table 1.  Recurring themes in responses of FSGS CT investigators to  post hoc survey. 
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study investigator team hindered enrollment. Th ese included test 
agent availability, fi nancial considerations, and contract execution 
timelines. Th e inability to obtain one of the study drugs that had 
been pledged to the trial resulted in a signifi cant delay in initiation 
of the trial. No explanation was provided by the pharmaceutical 
company for the delay in providing and ultimately deciding to 
withdraw material support for the trial. It is uncertain if more 
formal arrangements between investigators and those providing 
study agents can prevent this problem. However, there is precedent 
for delineation of the responsibilities of the drug sponsor in a 
memorandum of understanding draft ed before commencing a 
clinical trial. 8 Th e experience from the FSGS CT would suggest 
that making this a required step in the preparation for a study 
may help avoid unanticipated legal diffi  culties and delays in the 
performance of an RCT. Investigators identifi ed limited payment 
to patients based on prevailing local IRB standards; 3 limited per 
patient reimbursement to physicians because of sponsor-related 
funding constraints as specifi c fi nancial challenges to the FSGS 
CT. Finally, contract execution by academic institutions required 
an average of 7 months from the time of protocol dissemination. 
Th is contract timeline may have had a major adverse impact on 
the trial if all test agents were available. 
 Despite the importance of adequate recruitment of patients 
into pediatric clinical trials, there is not a great deal of published 
data focusing on this topic. 9 Most of the literature about the 
performance of RCT has been written by social scientists and is 
based on work performed at centers outside the United States. 
Th us, it may not be available to clinical nephrologists or directly 
applicable to their practice. In addition, there are almost no 
contributions that specifi cally address kidney diseases in general 
or focus on glomerulopathies. For example, in HIV vaccine trials, 
barriers to participation have been broken down into locus of 
the barrier (personal vs. social) and the nature of the barrier 
(risk vs. cost). 10 Reaching out directly to patients using disease 
specifi c Website or registries that target individuals with rare 
disorders can begin the process of surmounting patient related 
barriers to participation in clinical trials. 11,12 However, FSGS is 
more prevalent among minorities who may not have easy access to 
technology or Web-based marketing. Our data suggest that novel 
methods of communication using videos to introduce the study at 
the clinical sites are the highest rated recruitment tool compared 
to standard written material such as brochures, newsletters, and 
regional press releases. Research is needed to assess the effi  cacy 
of various recruitment tools in a variety of study environments. 
Th e role of Web-based marketing and the use of social networks 
require prospective evaluation particularly among populations 
who do not have easy access to this media. 
 We did not directly survey patients to determine whether there 
were features about the FSGS CT that may have discouraged them 
from consenting to the study. In addition, there is no information 
about patients who were approached about the trial but who 
declined to participate. Th is would have enabled a comparison 
between those who enrolled and those who refused. Issues of 
confi dentiality have hindered data collection from patients who 
opt out of a trial. Novel approaches for obtaining consent and 
collecting data about all potentially eligible research subjects in a 
given trial may assist in the design of strategies to foster enrollment 
during an ongoing study and for future trial development. 
 Physicians and other health care providers play a key role in 
recruitment into trials. Failure to invite every eligible patient to 
participate in a study may be due to simple inaction or investigators’ 
perception of the feasibility and soundness of the trial. 13 In our 
anonymous  post hoc survey of investigators, these concerns were 
indeed a barrier to participation as reported by 17/39 (44%) of the 
respondents. It was assumed that there was adequate physician buy-
in to the FSGS CT because the nephrologists were comprehensively 
surveyed about the availability of patients and their acceptance 
of the proposed treatment arms. Physician reluctance to enroll 
patients in the FSGS CT could have been underestimated if they 
were not forthcoming about their true opinions regarding the 
experimental treatments. Th e lack of consensus regarding the 
treatment arms, enhanced in part by the lack of a novel treatment 
modality, also played a role in dampening the enthusiasm of 
patients and physicians to participate in the study as noted in the 
 post hoc survey free text responses. Off ering innovative treatments 
could potentially overcome physician inertia in enrolling patients. 
However, this favorable eff ect might be counterbalanced by a 
hesitancy of physicians to move forward with a new therapy that 
has a worrisome or unknown side eff ect profi le. Th e availability 
of innovative treatments options may also enhance patient 
willingness to participate in a RCT. Th is is consistent with previous 
fi ndings in surveys indicating that the degree of perceived clinical 
benefi t is the most important factor fostering a greater likelihood 
of patient participation in an RCT. 14 
 One of the unique features of the FSGS CT was the wide age 
range for eligibility. Th e goal was to perform a study that would 
address the treatment of a broad sample of patients. However, this 
may have been an unacknowledged impediment to enrollment 
because site investigators may have assessed the potential toxicity 
of the test therapies diff erently dependent on whether they treated 
pediatric or adult patients. For example, extended treatment with 
dexamethasone may have been considered more hazardous in older 
patients with primary FSGS. Th is highlights the importance of full 
physician buy-in to a trial at its inception, during the planning 
phase, and through to successful enrollment and treatment. Based 
on the suboptimal enrollment into the FSGS CT, we can only 
encourage greater transparency by site investigators about the 
number of potential patients, acceptance of the study regimen, and 
accurate articulation of what they need to successfully identify and 
recruit study participants. Clarity on all of these points is essential 
to the Steering Committee of a trial and ensures optimal utilization 
of funding resources available for a study. 
 Th e long-time lag between initiating the IRB approval process 
and enrolling the fi rst patient at a site may also have undermined 
recruitment into the FSGS CT. Despite the use of multiple 
recruitment strategies, a delay of more than 12 months between 
distribution of a study protocol and initiation of enrollment 
into a trial may be an insurmountable obstacle to achievement 
of a recruitment target. Having a dedicated study coordinator, 
scientifi c leadership within the study team of investigators, and 
lectures by site investigators may also enhance commitment of 
physicians to a large RCT like the FSGS CT. 
 Optimal study design may diminish the problem of 
recruitment 15 and as reported by Luzi et al., 16 organized 
communication about an HIV vaccine study between the sponsor 
and physicians and patients involved in the project, enhanced 
physician buy-in and support for clinical trials. Improving 
procedures during screening and the informed consent process 
and the use of semi-automated systems to identify potential 
study participants have been utilized successfully to promote 
recruitment. 17,18 Finally, the role of payments to patients and 
families and balancing reimbursement for time spent on the study 
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versus coercion is an ethical issue that is oft en discussed as a 
patient barrier to enrollment. 19–21 Lack of suffi  cient reimbursement 
to off set transportation, childcare and work loss costs are barriers 
to enrollment and retention. In our survey of various institutional 
factors (IRB approval, execution of study contracts, support from 
the study infrastructure, and availability of personnel and fi nancial 
resources at the site), no single factor was clearly identifi ed as a 
hindrance or facilitator of patient recruitment. It is uncertain if 
this refl ects vague responses to the survey or a more fundamental 
failure to identify the root cause of poor enrollment into RCT. We 
acknowledge the limited response rate to the survey and recognize 
that it would be premature to generalize the fi ndings to RCT done 
in other subspecialties or in diff erent circumstances. 
 Th ere are several strengths of this report. First, in addition to 
describing recruitment before and aft er a large multicenter RCT, 
it incorporates a survey of site investigators aft er completion of 
the trial. Second, it depicts how recruitment into the study was 
addressed by ongoing issues that arose over the course of the 
trial. A major weakness is the low response (44%) to the survey 
which may have introduced a bias. Th ere is a lack of information 
about patients who refused to enroll in the study. Finally, there 
was no systematic collection of information about the sites, the 
demographics and qualifi cations of the personnel who supervised 
the study, and the actual fi nancial and research resources available 
to support the trial. 
 Th e FSGS CT addressed a disease that remains somewhat 
obscure to the general population. Patient advocacy groups 
like the NephCure Foundation and a registry for patients with 
the nephrotic syndrome that has been established by the NIH-
funded NEPTUNE cohort study are important tools to promote 
awareness of kidney disease. However, much work is still needed to 
publicize the importance and human cost of glomerular diseases 
such as FSGS and the need for clinical research. Th is may be a 
diffi  cult factor to control because of the individualized nature of 
medical care in the United States and the fi duciary responsibility 
to the individual patient, which may run counter to the ethic of 
participation in RCT. 
 Conclusion 
 Like many other trials, recruitment into the FSGS CT fell far short 
of the projected sample size, resulting in a study with limited power 
and diminished ability to achieve its objectives. In part, this refl ects 
the rarity of this glomerular disease, the lack of accurate patient 
census and informative registries at the potential recruitment 
sites, the paucity of suitable novel targets for phase III RCT, and 
a reluctance of nephrologists to relinquish their determination of 
individual patient treatment. Th ere were logistical issues such as 
the time required to obtain IRB approval and the lengthy process 
of executing a contract for the clinical research work that hinder 
recruitment. Most recruitment tools that are currently in use have 
not been studied systematically in a prospective manner and those in 
common use appear to have minimal impact on patient enrollment. 
Potential strategies to enhance recruitment into RCTs such as the 
FSGS CT include: Improved patient education about the severity 
of kidney disease, development of novel agents for testing in RCT, 
streamlining the start-up and regulatory approval process, increasing 
reimbursement to participating centers and study participants to 
cover the high institutional and participant costs incurred by clinical 
trials, and devising new strategies to communicate with patients and 
physicians before and during an RCT. 
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 Appendix: FSGS CT Investigators  post hoc Survey 
 Dear FSGS Trial Investigator, 
 Th e FSGS trial was the fi rst national study to helps us learn about eff ective treatments for patients with this challenging medical 
condition that carries such a poor prognosis, yet patient recruitment was diffi  cult. In an eff ort to learn about the potential barriers to 
enrollment, we would appreciate your candid responses. Be assured that this 7-question survey is ANONYMOUS and will take you 
5 or fewer minutes to complete. Your responses will guide future research eff orts. Before you begin, please have handy the answer to 
the fi rst question below.
  
1. Please tell us, how many patients were consented in the FSGS Clinical Trial at your site?
 2a. What is your practice setting (academic, private)
     Academic    Private
 2b. Who is your core Principal Investigator?
     D. Gipson    R. Kaskel  R. Fine/H. Trachtman
 2c. What age range of patients did you approach for the study?
     Children and adolescents only  Adults only   Children, adolescents and adults
 2d. What type of IRB did your study use for the trial?
     Institutional or local IRB   Your core institution’s IRB  A central IRB
 2e. What is your time zone?
     Pacifi c Time  Central Time   Mountain Time  Eastern Standard Time
3. How much did the eligibility criteria aff ect enrollment?
1 = Not at all 2 = Somewhat 3 = Quite a bit 4 = Absolutely Do not know
Patient age criterion
Trial medication regime
Prior treatment with drugs chosen for the FSGS trial
Patient weight criterion
 4a. Please specify the impact of other inclusion/exclusion criterion (open-ended question)
 4b. What could we have done diff erently to improve enrollment (open-ended question)
5. Please tell us the impact of the following factors on recruitment at your site …
1 = Major 
impediment




4 = Minor 
help
5 = Major 
help
Achieving consensus support for the trial in your 
group
Getting IRB approval
Executing a contract for the study
Support from the clinical cores
Availability of clinical coordinator for the trial
Adequacy of start up funds
Adequacy of the clinical per patient reimburse-
ment provided by the study
Availability of supplemental funds at your site
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6. Please tell us how helpful these tools were …
1 = Not at all 2 = Somewhat 3 = Quite a bit 4 = Absolutely Do not know/did not use






Participation in leadership committees 
for the FSGS Trial
7. Were there any solutions at your site that we need to be aware of? (open-ended question) 
 
